Status:
COMPLETED
COVID-19 and Disease Progression to the Severe Form: a Study on the Use of Monoclonal Antibodies Against SARS-CoV-2
Lead Sponsor:
University of Milano Bicocca
Conditions:
COVID-19
Eligibility:
All Genders
18+ years
Brief Summary
This is a national multicentre observational study with retrospective and prospective data collection to assess the time to hospitalisation of patients with a confirmed diagnosis of SARS-CoV-2 infecti...
Eligibility Criteria
Inclusion
- \>/= 18 years
- Confirmed diagnosis of SARS-CoV-2 infection
- Having received or receiving any anti-SARS-CoV-2 monoclonal antibody (or combination of monoclonal antibodies) prescribed through the AIFA registry
- Signature of informed consent (for subjects enrolled in the prospective part)
Exclusion
- Absence of criteria for prescribing monoclonal antibodies as determined by AIFA
- Patients already hospitalised for non-COVID reason at the time of monoclonal antibody administration
Key Trial Info
Start Date :
October 14 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 22 2023
Estimated Enrollment :
251 Patients enrolled
Trial Details
Trial ID
NCT05268601
Start Date
October 14 2021
End Date
December 22 2023
Last Update
March 30 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Asst-Monza Ospedale San Gerardo
Monza, Lombardy, Italy, 20900